The efficacy of topical Tranexamic Acid with and without using laser laser for treatment of melasma

Comparison of efficacy and safety of topical Tranexamic Acid with and without using non-ablative fractional Erbium glass in patients with melasma refering to Razi Hospital laser 1540nm for treatment of melasma in patients referred to Razi hospital

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016011626047N1

Enrollment

Registered

2016-04-24

Start date

2016-02-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

melasma. Chloasma

Interventions

Intervention 1: intervention group: topical tranexamic acid 5% in cold cream 2 times in a day withfractional erbium glass 1540nm(Sturlux) monthly. Intervention 2: control group: topical tranexamic

Treatment - Drugs

intervention group: topical tranexamic acid 5% in cold cream 2 times in a day withfractional erbium glass 1540nm(Sturlux) monthly

control group: topical tranexamic acid 5% in cold cream 2 times in a day

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: inclusion criteria: 18-65 years; symmetrical melasma in both half of the face; patients' satisfaction; skin type 1-5 exclusion criteria: use hidroquinone, topical and oral retinoid, topical steroid, alfa hydroxy acids and other drugs effect on pigmentation in past 4 weeks; use Oral Conterseptive Pill; chemical peeling,microderm abration, dermabratin or laser in past 3 months; history of past sensitivity to tranexamic acid; pregnancy; lactation; history ischemic or hemorrahgic events of coronal or cerebral artries

Exclusion criteria

Exclusion criteria:

Design outcomes

Secondary

Measure	Time frame
Topical advers effects. Timepoint: every month in intervention period and end of intervention. Method of measurement: questionnaire and observation.	—

Primary

Measure	Time frame
Pigmantation. Timepoint: before intervention,at the end of intervention,1 mouth and 3 mouths after end of intervention. Method of measurement: modified Melasma Area and Severity Index(mMASI) score,digital photography,patient satisfaction(questionnaire),physician assessment.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Zahra Shadlou

Tehran University of Medical Science

zshadlou@razi.tums.ac.ir; dr.z.shadlou@gmail.com+98 21 5563 0669

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026